Navigation Links
Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
Date:6/25/2008

However, the Average Number of Days of Inpatient Therapy per Patient Treated with an Antibiotic for MRSA Decreased by 10 Percent, According to

New Data Released by Arlington Medical Resources

MALVERN, Penn., June 25 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the number of patients treated with an antibiotic associated with a positive culture for MRSA within U.S. acute care hospitals has increased from 2006 to 2007 by 8 percent. However, the average number of days of inpatient therapy per patient treated with an antibiotic associated with a positive culture for MRSA decreased by 10 percent.

The newly released edition of The U.S. Hospital Antibiotic Market Guide finds that the most common infections among these patients with a positive culture for MRSA are:

-- Skin/skin structure infections (46 percent of patients)

-- Systemic infections (19 percent of patients)

-- Lower respiratory infections (19 percent of patients)

Why Pharmaceutical Companies Need this Information

The U.S. Hospital Antibiotic Market Guide allows pharmaceutical companies to quantify the clinical utilization of hospital antibiotics at a highly granular level in the United States. It is the most comprehensive data available to gain insights into clinical usage and prescriber dynamics of hospital antibiotics, including gram positive and gram negative agents.

"With a large pipeline of late-stage anti-MRSA products, biopharmaceutical companies are demanding accurate information on MRSA usage patterns and trends so they can understand the current market and how treatments will evolve with the launch of new anti-MRSA drugs," said Joyce Wedemeyer, product director at AMR. "The U.S. Hospital Antibiotic Market Guide allows marketing, new product planning, market research and marketing teams to understand how
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ASCO Results: Oncologists Rank Genentech Number One
2. Nikon Instruments Receives Record Number of Entries for Nikon Small World
3. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
4. Nanotubes grown straight in large numbers
5. BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates
6. The neural basis of number sense in young infants
7. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
8. New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
9. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
10. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., SANDIEGO,Nov.25/PRNewswire-FirstCall/--ArdeaB...rryD.Quart,Pharm.D.,presidentandchiefexecutiveoffi...reConference. , ,Presentationdetailsareasfollows:...Tuesday,December1,2009,Time:2:00p.m.EasternTime,Lo...href=,http://www.corporate-ir.net/ireye/,target=,...
(Date:11/24/2009)... The New York investment ban...(ASX:NEU) has agreed an AU$6.7 mil convertible not...stor. The private placement was arranged by KTA Ca...visor. , New York (PRWEB)...estment bank KTA Capital, LLC ("KTA Capital&q...
(Date:11/24/2009)..., ST.LOUIS,Nov.24/PRNewswire-FirstCall/--Sigma-...ttheNASDAQOMXconferenceonTuesday,December1stat1:45...tenvialiveaudiobroadcastovertheInternetavailableat...Userscanclickthe"Webcast"icontoaccessthisfile. ,...ifeScienceandHighTechnologycompany.Itschemicalandb...
(Date:11/24/2009)..., SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/-...ompanyfocusedondevelopingandcommercializingnovelpa...onno,PresidentandChiefExecutiveOfficer,isscheduled...erence,tobeheldDecember1-2,2009atTheNewYorkPalaceH...higlieri,ChiefFinancialOfficer,willbeavailabletore...
Breaking Biology Technology:Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
... Signalife, Inc.,(Amex: SGN ) has announced that... awarded the Company a new and important patent en...tbeats Of A Patient". The patent, which,covers 37 ...lop new,proprietary products., Patent attorneys f...patent application along with Chief Technology Off...
...Products Including Novel Nucleoside Analogue; New ... NEW YORK, April 23 MacroChem Corporation (OTC,Bu...18, 2008 it acquired,Virium Pharmaceuticals Inc., ... and commercializing novel therapeutics, with a po...ed in oncology, including its next,generation nucl...
...Champions,Biotechnology, Inc. (OTC Bulletin Board:...vanced preclinical platforms and tumor specific da...ed today the completion of a,$2,500,000 private fi...,Champions Biotechnology issued 1,428,572 restrict...er share. There were no fees or other expenses,rel...
Other Biology Technology:Signalife Awarded New U.S. Patent, 'System For, And Method Of, Monitoring Heartbeats Of A Patient' 2MacroChem Acquires Virium Pharmaceuticals 2MacroChem Acquires Virium Pharmaceuticals 3MacroChem Acquires Virium Pharmaceuticals 4MacroChem Acquires Virium Pharmaceuticals 5Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 2Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 3
(Date:11/23/2009)...d strain of the deadly superbug MRSAan infection-c...csposes a far greater health threat than previousl...rding to a study in the December issue of Emergin...ily picked up in fitness centers, schools, and oth...den of MRSA within hospitals, the report found. ,...
(Date:11/23/2009)...n Society says that western lowland gorillas livin... the "mother lode" of more than 125,000 gorillas d...tened by growing humans activity in the region. ,...ests adjacent to the southwest border of Lac Tl Co...t high densities of the great apes still exist in ...
(Date:11/23/2009)...incontrovertible evidence" that the volcanic super...3,000 years ago deforested much of central India, ...eport. , The volcano ejected an estimated 800 cu... a crater (now the world,s largest volcanic lake) .... Ash from the event has been found in India, the ...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Businesses Unions Veteran Party Leaders Unite Behind Bipartisan Consensus Approach to Health Care Reform 48325 1Businesses Unions Veteran Party Leaders Unite Behind Bipartisan Consensus Approach to Health Care Reform 48325 2Businesses Unions Veteran Party Leaders Unite Behind Bipartisan Consensus Approach to Health Care Reform 48325 3Businesses Unions Veteran Party Leaders Unite Behind Bipartisan Consensus Approach to Health Care Reform 48325 4Businesses Unions Veteran Party Leaders Unite Behind Bipartisan Consensus Approach to Health Care Reform 48325 5Businesses Unions Veteran Party Leaders Unite Behind Bipartisan Consensus Approach to Health Care Reform 48325 6Businesses Unions Veteran Party Leaders Unite Behind Bipartisan Consensus Approach to Health Care Reform 48325 7Impliant Granted Two New U S Patents and Successfully Defends European Patent Opposition Case 48321 1Impliant Granted Two New U S Patents and Successfully Defends European Patent Opposition Case 48321 2White Paper Explains Package Validation Requirements For Medical Devices 26 Combinatory Products 48317 1White Paper Explains Package Validation Requirements For Medical Devices 26 Combinatory Products 48317 2White Paper Explains Package Validation Requirements For Medical Devices 26 Combinatory Products 48317 3
...rchers Hao Yan and Yan Liu imagine and assemble in...small. Their medium is the double-helical DNA mole...limitless construction potential. , In the Janua...chers at ASU,s Biodesign Institute and faculty in ...al for the first time the three-dimensional charac...
...grape seeds forces laboratory leukemia cells to co...he University of Kentucky. They found that within ...ter being exposed to the extract. , The investiga...2009, issue of Clinical Cancer Research , a journ..., also teased apart the cell signaling pathway ass...
... soon will be one step closer to better drought-to...esearchers will construct a comprehensive database... compiled, the database will allow researchers to ...ans grown under drought and other stressed conditi...eased soybean genome, scientists will have a very ...
Other Biology News:The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 2The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 3Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds 2Soybean database will help breeders engineer better-performing plants 2
Buffer Dam for XCell SureLock and XCell II from Invitrogen
Rabbit Anti-Histone H2A Polyclonal Antibody, Unconjugated from BioVision
Rabbit Anti-Human EGFr, phospho (Tyr992) Concentrate Polyclonal Antibody, Unconjugated from Invitrogen
Rabbit Anti-Rat Synapsin I, phospho (Ser603) Monoclonal Antibody, Clone PS603 from Invitrogen
Biology Products: